Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence



Rating:

Share or cite this content

Citations should be made in the following way:
S. Korn (Mainz, Germany), A. Bourdin (Montpellier, France), G. Chupp (New Haven, United States of America), G. Colice (Gaithersburg, United States of America), C. Ambrose (Gaithersburg, United States of America), K. Kmita (Warsaw, Poland), J. Llanos-Ackert (Thousand Oaks, United States of America), N. Molfino (Thousand Oaks, United States of America), B. Cook (Gaithersburg, United States of America). Effect of tezepelumab on the proportion of exacerbation-free patients with severe, uncontrolled asthma in NAVIGATOR. 1198

Member's Comments

No comment yet.

Related content which might interest you: Effect of omalizumab on the risk of hospitalisation in patients with uncontrolled severe asthma in real-life. The PAX-LASER cohort Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Tezepelumab efficacy in patients with severe, uncontrolled asthma and comorbid nasal polyps in NAVIGATOR Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Efficacy of tezepelumab in adolescents with severe, uncontrolled asthma Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science Year: 2021 Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Oral corticosteroid (OCS)-sparing effect of tralokinumab in severe, uncontrolled asthma: the TROPOS study Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018 Effect of dupilumab on severe exacerbations in asthma patients with and without lung function improvements Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Effect of roflumilast in patients with severe COPD and a history of hospitalisation Source: Eur Respir J, 50 (1) 1700158; 10.1183/13993003.00158-2017 Year: 2017 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 “App” for uncontrolled moderate-severe asthma patients follow-up Source: International Congress 2017 – Biomarker-based asthma control Year: 2017 Long-term effect of roflumilast on exacerbations in patients with severe to very severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 526s Year: 2006 Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Effect of tralokinumab on GINA control in severe, uncontrolled asthma Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017 Prediction of the risk of future exacerbations in patients with severe persistent allergic asthma Source: Annual Congress 2005 - Severe asthma: perception and management Year: 2005 The 1-year cost-effectiveness of roflumilast for the treatment of severe to very severe COPD patients Source: Eur Respir J 2007; 30: Suppl. 51, 194s Year: 2007 Dupilumab reduces severe exacerbation-related costs among asthma patients: Results from a phase 2b trial Source: International Congress 2016 – How the increasing complexity of chronic care management challenges ethics and costs in our healthcare system Year: 2016 Evolution of patients with severe asthma treated with mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Reslizumab for uncontrolled eosinophilic asthma in patients who experienced a single exacerbation in the previous year: sub-analysis of two phase 3 trials Source: International Congress 2017 – Asthma management Year: 2017 Analysis of causes and quality of patients‘ treatment with often severe asthma exacerbations Source: Eur Respir J 2007; 30: Suppl. 51, 72s Year: 2007 Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma Source: ERJ Open Res, 6 (1) 00204-2019; 10.1183/23120541.00204-2019 Year: 2020